Status:
RECRUITING
Left Atrial Volume Changes Who Underwent Cardioversion and Recurrence of AF After RF Ablation in Persistent AF (SAFE-AF)
Lead Sponsor:
The Second Affiliated Hospital of Chongqing Medical University
Conditions:
Persisent Atrial Fibrillation
Reversal of Atrial Enlargement
Eligibility:
All Genders
18+ years
Brief Summary
Electrical/pharmacological cardioversion improves structural remodeling of left atrium. We hypothesize that persistent atrial fibrillation (AF) patients with more significant left atrial size reductio...
Detailed Description
Background: Atrial fibrillation (AF) is estimated to affect over 33 million people worldwide and is associated with significant co-morbidities such as embolic stroke, heart failure, dementia. Conseque...
Eligibility Criteria
Inclusion
- Patients with estabolished diagnosis of Persistent Atrial Fibrillation during past 6 mnths.
- LAD brfore entering the two cohorts is more than 40mm, and less than 50mm.
- Pharmacological or electrical cardioversion has be performed successfully.
- At least two echocardiograms were performed before and 3-6 months after cardioversion., and confirm the status of LAD (Reversal, unchange, enlargment).
- Patients have given informed consent.
Exclusion
- Prior radiofrequency ablation treatment for atrial fibrillation
- Prior cardiac surgical procedures
- Individuals with cognitive impairments who are unable to give informed consent
Key Trial Info
Start Date :
July 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06523738
Start Date
July 1 2019
End Date
December 31 2025
Last Update
July 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400072